期刊文献+

抗白细胞介素-12抗体在银屑病应用中的研究进展

下载PDF
导出
摘要 银屑病是一种常见的红斑鳞屑性皮肤病,其发病机制尚未清楚,多种细胞因子参与了该病的发生与发展,研究认为白细胞介素-12(IL-12)在银屑病发病过程中起重要作用,使用抗IL-12抗体对银屑病分别开展了Ⅰ、Ⅱ、Ⅲ期临床实验,发现抗IL-12抗体可明显缓解银屑病症状,目前研究认为具有良好的安全性。现就抗IL-12抗体在银屑病治疗中的应用作一简要综述。
作者 陈传杰 陆春
出处 《中国麻风皮肤病杂志》 2010年第1期41-43,共3页 China Journal of Leprosy and Skin Diseases
  • 相关文献

参考文献15

  • 1Norris DA, Travers JB, Leung DYM. Lymphocyte cativation in the pathogenesis of psoriasis. J Invest Dermatol 1997; 109:1 - 4.
  • 2Yawalkar N, Karlen S, Hunger R. Expression of interleukin 12 is increased in psoriatic skin. J Invest Dermatol 1998; 111 (6) : 1053 -1057.
  • 3Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and P40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125- 130.
  • 4Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin - 12 P40 gene (IL12B) 3' - untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002;30(2) :161 - 166.
  • 5Hong K, Chu A, badviksson BR, et al. IL- 12, independently of IFN- gamma, plays a crucial role in the pathogenesis of a murine w, oriasis-like skin disorder. J Immunol 1999; 162:7480- 7491.
  • 6Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6) :580 - 592.
  • 7Toichi E, Tortes G, McCormick TS, et al. An anti - IL - 12 P40 antibody down- regulates type 1 cytokines, chemokines, and IL- 12/IL - 23 in psoriasis. J Immunol 2006; 177(7) :4917 - 4926.
  • 8Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL- 12R, CD40L, and IL - 2R alpha expression and inhibition of IL - 12 - and IL-23 - induced cytokine secretion by CNTO 1275. Cell Immunol 2007:247(1): 1 - 11.
  • 9Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and chnical response of a human IL - 12 P40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123 : 1037 - 1044.
  • 10Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76 - week results from a randonfised, double - blind, placebo- controlled trial (PHOENIX 1 ). Lancet 2008;371 (%25) : 1665 - 1674.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部